For those willing to invest in the right capabilities, offering patient services can give pharma companies a tremendous opportunity.
Clinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.
How companies can better integrate valuable data across business functions to meet rising value-chain demands.
How companies can better integrate valuable data across business functions to meet rising value-chain demands.
How companies can better integrate valuable data across business functions to meet rising value-chain demands.
How companies can better integrate valuable data across business functions to meet rising value-chain demands.
BCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.
The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
It is essential to ensure the safety profiles of potential COVID-19 therapies are supported by robust data so that healthcare providers and physicians can make appropriate, evidence-based decisions, writes Dr. Andrew Rut.
A look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA
Pharma's challenge is to break the cycle of mistrust so that its pioneering work can fully reach patients in need, writes GSK's Murray Stewart.
Highly skilled pharma staff are obliged to devote hours to routine administrative tasks updating product information. Technology can free them from this burden, writes Dr. Jutta Hohenhörst.
Companies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.
In the healthcare industry, “patient centricity” is like comfort food – everyone knows what it is, but it can mean very different things to different people.
Sponsored contentThe term “patient centric” has become an almost catch-all term. Cheryl Lubbert looks at the broad range of its application. A review of how patient centricity is being applied shows that it is all of these things and more. A look at just a few different uses of the term shows the broad range of its application:
FDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.
Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.
Technology is more critical than ever to help you keep your clinical trials on track during the era of COVID-19. Gain best practices about how to empower your remote workforce, get critical regulated documents electronically signed compliantly, and to create a safe and flexible remote patient-centric experience. Live: Wednesday, Jul. 15, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Jul. 15, 2021. Register free
Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.
If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.
Balancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.
Increased scrutiny and new regulation have seen pharma’s relationship with key opinion leaders (KOLs) undergo a paradigm shift in recent years.
Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Outlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.